EDITORIAL INDEX, 1972-73

(Covers all articles and Washington Briefs published from Volume 1, Number 1, to the present)

ADVERTISING

Choosing the ad agency to fit your product, 9/72, p. 59

Moss sees 'nothing but hot air' behind many ad claims (Washington Brief), 9/72, p. 5

FTC clarifies guidelines on ad allowances (Washington Brief), 10/72, p. 7

FTC cracks down on comparative ad demonstrations (Washington Brief), 10/72, p. 9

FDA warns about 'unwarranted' Rx ad claims (Washington Brief), 10/72, p. 12

Counter-advertising would destroy present system of broadcasting: NAB (Washington Brief), 11/72, p. 9

Survey reinforces FDA view that it, not FTC, should control OTC ads (Washington Brief), 11/72, p. 11

Direct mail: a neglected medium?, 12/72, p. 65

Point-of-purchase advertising: it sells where people buy, 1/73, p. 27

FTC ad program will hit at major sales targets (Washington Brief), 2/73, p. 8

Living with tougher ad restrictions, 2/73, p. 30

Specialty advertising: gifts that build sales, 2/73, p. 44

FTC calls for cold remedy formulas in ad-claim probe (Washington Brief), 3/73, p. 5

PA, broadcasters adopt guidelines for TV advertising (Washington Brief), 4/73, p. 9

The consumer agency vs. the specialized agency: which is best for medical advertising?, 4/73, p. 54

New push coming for free 'counter ads' (Washington Brief), 5/73, p. 8

FTC seeks funds for attack on drug, cosmetic ads (Washington Brief), 6/73, p. 6

Do testimonials really work?, 6/73, p. 25

New FTC chief presses ad substantiation demands (Washington Brief), 7/73, p. 6

Mood drug ads seek to suppress women, group charges (Washington Brief), 7/73, p. 8

Can the multi-product 30-second spot succeed?, 7/73, p. 57

Industry, FTC face showdown on corrective advertising (Washington Brief), 8/73, p. 10

Consumerist 'counter ads' may not be aired (Washington Brief), 8/73, p. 14

1972 ad expenditures for health and beauty aids, 8/73, p. 44

FTC ready for action on TV vitamin ads directed at kids (Washington Brief), 9/73, p. 21

Ads that cite the competition: a new trend?, 9/73, p. 58

Dark Eyes: what attention-getting ads can do, 9/73, p. 84

Does humor in advertising work?, 10/73, p. 28

FDA signs up ad agency for drug information campaign (Washington Brief), 11/73, p. 4

FTC ad-proof drive stalls; firms' data confound staff, consumers (Washington Brief), 11/73, p. 4

How to work with your ad agency, 11/73, p. 25

AEROSOLS

Nader aides ask action on aerosol explosion hazard (Washington Brief), 1/73, p. 6

A new look at aerosol safety, 1/73, p. 21

Speedup on issuance of aerosol safety standards sought (Washington Brief), 3/73, p. 7

Aerosol label warning against inhalation is proposed (Washington Brief), 4/73, p. 12

Aerosols: the search for a safer container, 6/73, p. 46

ALBERTO-CULVER

Can the multi-product 30-second spot succeed?, 7/73, p. 57

ANGEVINE, ERMA

Consumerism today and what it means to the marketer, 12/73, p. 51

ANTITRUST ACTION

Victors fight over spoils of antibiotic antitrust suit (Washington Brief), 9/73, p. 21

Drug makers get a breather on antitrust hearings (Washington Brief), 9/73, p. 24.

Congress moves to publicize settlements in antitrust suits (Washington Brief), 11/73, p. 4

AUDIOVISUALS

Should you be spending more on audio-visual aids?, 12/72, p. 46

Ciba tries a videotaped sales meeting, 9/73, p. 86

BASSIN, AMELIA

A critic looks at cosmetic marketing, 10/72, p. 50

BRISTOL LABORATORIES

Bristol snaps up rights to cancer institute's drug (Washington Brief), 2/73, p. 8

BRISTOL-MYERS

How Vitalis stays on top, 9/72, p. 41

BUREAU OF NARCOTICS AND DANGEROUS DRUGS

See **Drug Enforcement Administration**

CARTER-WALLACE

Carter-Wallace loses appeal on meprobamate patent (Washington Brief), 7/73, p. 6

CHANEL

Marketing case history: Chanel No. 19, 5/73, p. 42

CHESEBROUGH-POND'S

Marketing case history: the Vaseline Intensive Care line, 10/72, p. 72

CIBA

Ciba tries a videotaped sales meeting, 9/73, p. 86

COMPUTER TIME-SHARING

How computer power can improve your decision-making, 12/72, p. 29

CONGRESS

Ellender successor cool to consumer agency bill (Washington Brief), 9/72, p. 7

Moss sees 'nothing but hot air' behind many ad claims (Washington Brief), 9/72, p. 5

Passage of consumer product bill expected (Washington Brief), 10/72, p. 7

Outpatient drug bill is revived by Senator

EDITORIAL INDEX, 1972-73

Hartke (Washington Brief), 10/72, p. 7

Adjournment may snag consumer agency bill (Washington Brief), 10/72, p. 12

White House blamed for death of consumer protection bill (Washington Brief), 11/72, p. 5

Nelson introduces bill to curb 'pricing excesses' (Washington Brief), 11/72, p. 5

Sen. Gaylord Nelson vs. the drug industry, 11/72, p. 91

GAO approval of unit-dose system could influence Congress (Washington Brief), 1/73, p. 5

Nelson presses hearings; scientists attack ads, overprescribing (Washington Brief), 1/73, p. 5

Democrats' thrust for aggressive image may hurt industry (Washington Brief), 1/73, p. 5

House action on cosmetic ingredient labeling remains doubtful (Washington Brief), 2/73, p. 5

Law would require product labels to reveal name of actual maker (Washington Brief), 2/73, p. 5

Fountain plans hearings on FDA's 'abuse of power' (Washington Brief), 2/73, p. 7

Nelson's FD&C Act amendments due for replay this session (Washington Brief), 4/73, p. 12

Drug industry not major target of Senator Hart (Washington Brief), 5/73, p. 8

Ribicoff puts off hearings on Biologics Bureau (Washington Brief), 7/73, p. 8

Confrontation with White House looms over Kennedy's HMO bill (Washington Brief), 7/73, p. 10

FDA nixes Senator's request for OTC-type review of cosmetics (Washington Brief), 8/73, p. 8

Senator Nelson attacks industry's domestic price schedules (Washington Brief), 8/73, p. 10

Consumers urge Congress to bar FDA vitamin-mineral proposal (Washington Brief), 8/73, p. 10

Kennedy drug-industry hearings could bring restrictive new laws (Washington Brief), 9/73, p. 8

Revolutionary patent-law proposals to be aired by Senate (Washington Brief), 9/73, p. 8

Congress considers cut-rate buying rights for U.S. grantees (Washington Brief), 9/73, p. 24

Eagleton cosmetic control bill faces some cuts (Washington Brief), 10/73, p. 6

FDA faces Senate grilling over charges of laxity on INDs (Washington Brief), 11/73, p. 4

Congress moves to publicize settlements in antitrust suits (Washington Brief), 11/73, p. 4

Congress may soon curb taxing powers of states (Washington Brief), 11/73, p. 11

CONSUMER EXPENDITURES

What the public spent for drugs, cosmetics, toiletries in 1971, 9/72, p. 33

What the public spent for drugs, cosmetics, toiletries in 1972, 10/73, p. 43

CONSUMERISM

Ellender successor cool to consumer agency bill (Washington Brief), 9/72, p. 7

Passage of consumer product bill expected (Washington Brief), 10/72, p. 7

Adjournment may snag consumer agency bill (Washington Brief), 10/72, p. 12

White House blamed for death of consumer protection bill (Washington Brief), 11/72, p. 5

Nader aides ask action on aerosol explosion hazard (Washington Brief), 1/73, p. 6

Restrict detail man's presentations, consumerists urge (Washington Brief), 2/73, p. 8

Consumerist wants FTC to demand cosmetic complaint files (Washington Brief), 3/73, p. 5

Consumerism still holds sway despite shift of Knauer's unit (Washington Brief), 3/73, p. 8

Consumerists and feminists vs. the vaginal spray, 3/73, p. 30

Lilly plays down side effects of Ilosone, Nader group asserts (Washington Brief), 6/73, p. 10

Mood drug ads seek to suppress women, group charges (Washington Brief), 7/73, p. 8

Consumers urge Congress to bar FDA vitamin-mineral proposal (Washington Brief), 8/73, p. 10

Consumerist 'counter ads' may not be aired (Washington Brief), 8/73, p. 14

Knauer may seek cosmetic, drug complaint center (Washington Brief), 10/73, p. 9

Consumer safety panel eyes drug packaging, OTCs (Washington Brief), 10/73, p. 12

Consumerism today and what it means to the marketer, 12/73, p. 51

COSMETIC, TOILETRY, AND FRAGRANCE ASSOCIATION

CTFA opposes cosmetic adverse-reaction guidelines (Washington Brief), 4/73, p. 9

CTFA offers plan for filing 'reportable experiences' (Washington Brief), 6/73, p. 12

CTFA expects FDA to accept its complaint screening plan (Washington Brief), 7/73, p. 8

COSMETICS/TOILETRIES

The small cosmetic company: an endangered species?, 9/72, p. 28

How Vitalis stays on top, 9/72, p. 41

The manufacturer-supplier relationship in the fragrance industry, 9/72, p. 52

A critic looks at cosmetic marketing (interview with Amelia Bassin), 10/72, p. 50

Trouble in the hair-color market, 11/72, p. 38

Marketing case history: How Mitchum cracked the antiperspirant market, 12/72, p. 35

Fragrance marketing: French tradition vs. American innovation, 12/72, p. 39

How Rubinstein beats lack of assistance in self-service stores, 1/73, p. 47

FDA issues final regulations on use of mercury in cosmetics (Washington Brief), 2/73, p. 5

House action on cosmetic ingredient labeling remains doubtful (Washington Brief), 2/73, p. 5

Marketing case history: can a new fragrance succeed in the off-season? 2/73, p. 20

Consumerist wants FTC to demand cosmetic complaint files (Washington Brief), 3/73, p. 5

FDA moves for mandatory ingredient labeling (Washington Brief), 3/73, p. 8

Cosmetic regulation: how much this year? 3/73, p. 25

Consumerists and feminists vs. the vaginal spray, 3/73, p. 30

Marketing case history: Jean Naté: selling the bath as a pleasurable experience, 3/73, p. 35

John Revson's innovative approach to marketing, 3/73, p. 52

CTFA opposes cosmetic adverse-reaction guidelines (Washington Brief), 4/73, p. 9

Marketing case history: Mennen E: creating a deodorant with a difference, 4/73, p. 39

Judge in Dry Ban case wonders how dry is 'dry' (Washington Brief), 5/73, p. 12

Marketing case history: Chanel No. 19, 5/73, p. 42

Is peach going to replace lemon?, 5/73, p. 76

Feminine sprays are cosmetics, not drugs, FDA holds (Washington Brief), 6/73, p. 6

Knauer calls for ingredient labeling for perfumes (Washington Brief), 6/73, p. 10

Do testimonials really work?, 6/73, p. 25

Proprietary Perfumes Ltd. enters the U.S. market, 6/73, p. 63

CTFA offers plan for filing 'reportable experiences' (Washington Brief), 6/73, p. 12

CTFA expects FDA to accept its complaint screening plan (Washington Brief), 7/73, p. 8

Private labels: growing factor in the HBA field, 7/73, p. 21

Marketing case history: Love: how to launch a cosmetic line, 7/73, p. 26

Marketing case history: Cover Girl, 7/73, p. 38

FDA nixes Senator's request for OTC-type review of cosmetics (Washington Brief), 8/73, p. 8

Cosmetic complaints: how industry handles them, 8/73, p. 27

The short unhappy life of Mennen E, 8/73, p. 28

How Chap Stick came in from the cold, 8/73, p. 61

Trade commission study of cosmetic industry still not finished (Washington Brief), 9/73, p. 8

The scramble for the $400-million shampoo market, 9/73, p. 35

Dark Eyes: what attention-getting ads can do, 9/73, p. 84

FDA launches survey of adverse reactions to cosmetics (Washington Brief), 10/73, p. 6

Eagleton cosmetic control bill faces some cuts (Washington Brief), 10/73, p. 6

How Estée Lauder planned for Christmas 1973, 10/73, p. 33

Action on bubble baths seen as complaints continue (Washington Brief), 11/73, p. 8

Germaine Monteil: How to compete with the giants, 12/73; p. 28

COTY

Product management at Coty: the total marketing concept, 11/72, p. 48

CROUT, J. RICHARD

The Bureau of Drugs: less red tape ahead?, 11/73, p. 34

DARK EYES CO.

Dark Eyes: what attention-getting ads can do, 9/73, p. 84

DE HAEN, PAUL

Pitfalls in the analysis of new drug introductions, 11/73, p. 48

DETAILING

Restrict detail man's presentations, consumerists urge (Washington Brief), 2/73, p. 8

Medical promotion to the young MD, 6/73, p. 38
Detail man is 'on the way out,' FDA commissioner holds (Washington Brief), 11/73, p. 11

DIRECT MAIL

Direct mail: a neglected medium?, 12/72, p. 65

DIVESTITURE

Divestiture: how product pruning can stimulate growth, 9/73, p. 78

DRUG ENFORCEMENT ADMINISTRATION

BNDD chief scores pharmaceutical industry (Washington Brief), 11/72, p. 9
Federal narcotics units probably will merge (Washington Brief), 5/73, p. 6
Methaqualone control may mean new abuse category (Washington Brief), 5/73, p. 12
BNDD readies tighter controls on nine barbiturates (Washington Brief), 6/73, p. 6

DRUG SAFETY

Senator Kennedy eyes curbs on human experimentation (Washington Brief), 9/72, p. 5
Ellender successor cool to consumer agency bill (Washington Brief), 9/72, p. 7
Passage of consumer product bill expected (Washington Brief) 10/72, p. 7
Adjournment may snag consumer agency bill (Washington Brief), 10/72, p. 12
White House blamed for death of consumer protection bill (Washington Brief), 11/72, p. 5
French tragedy sealed fate of hexachlorophene (Washington Brief), 11/72, p. 5
How safe can drugs be?, 11/72, p. 33
FDA chiefs defend tight rules on human drug regulations (Washington Brief), 3/73, p. 7
No legal curbs on human tests are needed, Stetler holds (Washington Brief) 4/73, p. 12
FDA studies Canadian's research report critical of APC (Washington Brief), 4/73, p. 15
Vaccine efficacy review draws protests from MDs, patients (Washington Brief), 4/73, p. 15
The 1962 drugs amendments: time for an overhauling?, 5/73, p. 27
Lilly plays down side effects of Ilosone, Nader group asserts (Washington Brief), 6/73, p. 10
FDA permits 'unavoidable bacteriophages' in vaccines (Washington Brief), 6/73, p. 12
Biologics review may doom many low-volume products (Washington Brief), 7/73, p. 6
What to expect from the efficacy review of biologics, 8/73, p. 36
Experts may seek limits on antibiotics given preoperatively (Washington Brief), 9/73, p. 21
FDA faces Senate grilling over charges of laxity on INDs (Washington Brief), 11/73, p. 4
Pitfalls in the analysis of new drug introductions, 11/73, p. 48

FEDERAL TRADE COMMISSION

Moss sees 'nothing but hot air' behind many ad claim. (Washington Brief), 9/72, p. 5
The revitalized FTC: aims and implications, 9/72, p. 46
FTC clarifies guidelines on ad allowances (Washington Brief), 10/72, p. 7
FTC cracks down on comparative ad demonstrations (Washington Brief), 10/72, p. 9
Survey reinforces FDA view that it, not FTC, should control OTC ads (Washington Brief), 11/72, p. 11
FTC rejects bid to outlaw push money (Washington Brief), 12/72, p. 5
Exclusive distributorships face attack (Washington Brief), 12/72, p. 5
FTC issues trade rules despite court (Washington Brief), 12/72, p. 7
FDA proposes cosmetic reaction reporting plan (Washington Brief), 12/72, p. 7
Changes at top may slow FTC activity (Washington Brief), 12/72, p. 7
FTC may demand sales breakdowns (Washington Brief), 12/72, p. 8
FTC moving on four key drug-cosmetic merger cases (Washington Brief), 1/73, p. 6
FTC plans probe of drug industry's market structure (Washington Brief), 2/73, p. 5
FTC prepares certification, 'seal of approval' programs (Washington Brief), 2/73, p. 7
FTC ad program will hit at major sales angles (Washington Brief), 2/73, p. 8
Living with tougher ad restrictions, 2/73, p. 30
Consumerist wants FTC to demand cosmetic complaint files (Washington Brief), 3/73, p. 5
Magnuson pushes bill to give FTC rule-making authority (Washington Brief), 3/73, p. 5
FTC calls for cold remedy formulas in ad-claim probe (Washington Brief), 3/73, p. 5
FDA wins big 15% budget hike; FTC's gain is mere 4% (Washington Brief), 3/73, p. 8
Engman confident that Court will uphold FTC on trade rules (Washington Brief), 5/73, p. 6
Judge in Dry Bar case wonders how dry is 'dry' (Washington Brief), 5/73, p. 12
FTC seeks funds for attack on drug, cosmetic ads (Washington Brief), 6/73, p. 6
Cosmetic firm charged with making false claims for ingredient (Washington Brief), 6/73, p. 6
New FTC chief presses ad substantiation demands (Washington Brief), 7/73, p. 6
FTC eyes medical supplies field for anti-trust violations (Washington Brief), 7/73, p. 10
Which way the new FTC?, 7/73, p. 17
Court upholds FTC's authority to issue binding rules (Washington Brief), 8/73, p. 8
Industry, FTC face showdown on corrective advertising (Washington Brief), 8/73, p. 10
Trade commission study of cosmetic industry still not finished (Washington Brief), 9/73, p. 8
Shifts at FTC aimed at reducing case-by-case lawsuits (Washington Brief), 9/73, p. 21
FTC ready for action on TV vitamin ads directed at kids (Washington Brief), 9/73, p. 21
FTC pressing for breakdowns of industry sales (Washington Brief), 10/73, p. 6
FTC curbs 'rejuvenation' by peeling layers of skin (Washington Brief), 10/73, p. 6
FTC weighs antitrust action against group drug buying (Washington Brief), 10/73, p. 12
Where FDA and FTC rule-making is going, 11/73, p. 66
FTC ad-proof drive stalls; firms' data confound staff, consumers (Washington Brief), 11/73, p. 4
FTC to push 'information disclosure,' ex-counsel predicts (Washington Brief), 11/73, p. 4
Budget office may give FTC product-sales figures (Washington Brief), 11/73, p. 8

FEED ADDITIVES

SK&F readies NDA data on nonhormonal feed additive (Washington Brief), 9/72, p. 7

FOOD ADDITIVES

The search for a new artificial sweetener, 10/72, p. 27
Why FDA would like to see the Delaney Amendment eased (Washington Brief), 11/72, p. 5
Abbott to revive cyclamate food-additive petition (Washington Brief), 10/73, p. 9

FOOD AND DRUG ADMINISTRATION

FDA weighs consumerist, industry views on disclosure (Washington Brief), 9/72, p. 5
Setting amphetamine quota poses problem for FDA (Washington Brief), 9/72, p. 5
Senate plans review of FDA's IND regulations (Washington Brief), 9/72, p. 5
FDA rejects diabetes group's plea on hypoglycemics (Washington Brief), 9/72, p. 7
Court restores NDA for USV's bioflavonoid (Washington Brief), 10/72, p. 9
Court finds FDA delayed action on efficacy review (Washington Brief), 10/72, p. 9
FDA reinterprets NAS-NRC box regulations (Washington Brief), 10/72, p. 12
Procedures for biologicals review proposed (Washington Brief), 10/72, p. 12
FDA warns about 'unwarranted' Rx ad claims (Washington Brief), 10/72, p. 12
An exclusive interview with Dr. Herbert Ley, 10/72, p. 37
French tragedy sealed fate of hexachlorophene (Washington Brief), 11/72, p. 5
Why FDA would like to see the Delaney Amendment eased (Washington Brief), 11/72, p. 5
Rx-only sale of narcotic drugs would hit consumer in the pocketbook (Washington Brief), 11/72, p. 9
PMA attacks proposed environmental impact statements (Washington Brief), 11/72, p. 11
Court bars PMA intervention in complaint against FDA (Washington Brief), 11/72, p. 11
Survey reinforces FDA view that it, not FTC, should control OTC ads (Washington Brief), 11/72, p. 11
FDA rules DESI notices apply to 'me-too' drugs (Washington Brief), 12/72, p. 5
Price listing is outside FDA's sphere, PMA holds (Washington Brief), 12/72, p. 5
FDA proposes cosmetic reaction reporting plan (Washington Brief), 12/72, p. 7
Court rebuffs FDA on antidiabetic drug labeling (Washington Brief), 12/72, p. 8
FDA bans HCP in feminine sprays, limits other uses (Washington Brief), 12/72, p. 8
Two court cases challenge FDA's regulatory powers (Washington Brief), 1/73, p. 5
FDA issues final regulations on use of mercury in cosmetics (Washington Brief), 2/73, p. 5

Secrecy pledged on environmental impact data (Washington Brief), 2/73, p. 7

Fountain plans hearings on FDA's 'abuse of power' (Washington Brief), 2/73, p. 7

Will methadone dispensing regs set a precedent? (Washington Brief), 2/73, p. 7

FDA clarifies rules for bioavailability testing (Washington Brief), 2/73, p. 8

Retain OTC status for codeine products, FDA's advisors urge (Washington Brief), 3/73, p. 7

FDA chiefs defend tight rules on human drug regulations (Washington Brief), 3/73, p. 7

FDA wins big 15% budget hike; FTC's gain is mere 4% (Washington Brief), 3/73, p. 8

FDA moves for mandatory cosmetic ingredient labeling (Washington Brief), 3/73, p. 8

June 30 deadline is set for registering, coding drugs (Washington Brief), 4/73, p. 9

CTFA opposes cosmetic adverse-reaction guidelines (Washington Brief), 4/73, p. 9

Aerosol label warning against inhalation is proposed (Washington Brief), 4/73, p. 12

FDA panel may ban all antibacterials from vaginal sprays (Washington Brief), 4/73, p. 12

FDA studies Canadian's research report critical of APC (Washington Brief), 4/73, p. 15

Vaccine efficacy review draws protests from MDs, patients (Washington Brief), 4/73, p. 15

FDA rules for nutrients place vitamins' status in doubt (Washington Brief), 4/73, p. 15

The 1962 drug amendments: time for an overhauling?, 5/73, p. 27

FDA called lax in enforcing GMP compliance (Washington Brief), 5/73, p. 6

Antacid panel calls for wide label changes (Washington Brief), 5/73, p. 6

FDA's trade secret act not yet final (Washington Brief), 5/73, p. 8

Methaqualone control may mean new abuse category (Washington Brief), 5/73, p. 12

12-tablet aspirin packs gain short reprieve (Washington Brief), 5/73, p. 12

Feminine sprays are cosmetics, not drugs, FDA holds (Washington Brief), 6/73, p. 6

Deadline is set for safety packaging of oral Rx drugs (Washington Brief), 6/73, p. 10

FDA OTC dental review panel begins deliberations (Washington Brief), 6/73, p. 10

PMA protests abrupt action banning Violet No. 1 (Washington Brief), 6/73, p. 12

FDA permits 'unavoidable bacteriophages' in vaccines (Washington Brief), 6/73, p. 12

CTFA offers plan for filing 'reportable experiences' (Washington Brief), 6/73, p. 12

FDA cough/cold guides 'poorly conceived,' PMA asserts (Washington Brief), 7/73, p. 6

Biologics review may doom many low-volume products (Washington Brief), 7/73, p. 6

CTFA expects FDA to accept its complaint screening plan (Washington Brief), 7/73, p. 8

Ribicoff puts off hearings on Biologics Bureau (Washington Brief), 7/73, p. 8

FDA exempts diagnostic reagents from drug listing rule (Washington Brief), 7/73, p. 10

What to expect from the efficacy review of biologics, 8/73, p. 36; 10/73, p. 12

FDA to speed up processing of new drug applications (Washington Brief), 8/73, p. 8

FDA nixes Senator's request for OTC-type review of cosmetics (Washington Brief), 8/73, p. 8

FDA's Bureau of Drugs favors good management, not innovation (Washington Brief), 8/73, p. 10

Consumers urge Congress to bar FDA vitamin-mineral proposal (Washington Brief), 8/73, p. 10

Court nixes plea on diabetes drugs; orders FDA to reconsider labeling (Washington Brief), 9/73, p. 8

Experts may seek limit on antibiotics given preoperatively (Washington Brief), 9/73, p. 21

Trichloroethane order is FDA's first use of listing-act power (Washington Brief), 9/73, p. 24

FDA launches survey of adverse reactions to cosmetics (Washington Brief), 10/73, p. 6

HEW, FDA in conflict over trade data secrecy (Washington Brief), 10/73, p. 9

FDA would delay action on Rx cough-cold drugs (Washington Brief), 10/73, p. 12

The Bureau of Drugs: less red tape ahead?, 11/73, p. 34

Pitfalls in the analysis of new drug introductions, 11/73, p. 48

Where FDA and FTC rule-making is going, 11/73, p. 66.

FDA faces Senate grilling over charges of laxity on INDs (Washington Brief), 11/73, p. 4

FDA signs up ad agency for drug information campaign (Washington Brief), 11/73, p. 4

Action on bubble baths seen as complaints continue (Washington Brief), 11/73, p. 8

Future of OTCs bright, Hutt tells industry lawyers (Washington Brief), 11/73, p. 8

Detail man is 'on the way out,' FDA commissioner holds (Washington Brief), 11/73, p. 11

FRAGRANCES

The manufacturer-supplier relationship in the fragrance industry, 9/72, p. 52

Fragrance marketing: French tradition vs. American innovation, 12/72, p. 39

Marketing case history: can a new fragrance succeed in the off-season?, 2/73, p. 20

Marketing case history: Chanel No. 19, 5/73, p. 42

Is peach going to replace lemon?, 5/73, p. 76

Proprietary Perfumes Ltd. enters the U.S. market, 6/73, p. 63

Knauer calls for ingredient labeling for perfumes (Washington Brief), 6/73, p. 10

Lanvin's two new fragrances rely on fashion, glamour, 11/73, p. 38

HEALTH, EDUCATION, AND WELFARE, DEPARTMENT OF

HEW may ask industry to foot bill for services (Washington Brief), 10/73, p. 9

HEW, FDA in conflict over trade data secrecy (Washington Brief), 10/73, p. 9

JUSTICE DEPARTMENT

Tetracycline fraud case may still bring Congressional hearings (Washington Brief), 10/72, p. 7

Exclusive distributorships face attack (Washington Brief), 12/72, p. 5

Justice Department seeks power to challenge patents (Washington Brief), 1/73, p. 6

LANVIN/CHARLES OF THE RITZ

Marketing case history: Jean Naté: selling the bath as a pleasurable experience, 3/73, p. 35

Lanvin's two new fragrances rely on fashion, glamour, 11/73, p. 38

LAUDER, ESTÉE

How Estée Lauder planned for Christmas 1973, 10/73, p. 33

LEY, HERBERT M. JR.

An exclusive interview with Dr. Herbert Ley, 10/72, p. 37

MANAGEMENT

When should marketing take over from product development?, 3/73, p. 68

How to cope with the paper-work jungle, 3/73, p. 40

Marketing and R&D: natural enemies?, 5/73, p. 33

The marketing plan: just for show?, 7/73, p. 31

How to calculate the payout on a marketing program, 12/73, p. 23

What I don't like about the marketing department, 12/73, p. 32

MARKETING CASE HISTORIES

How Vitalis stays on top, 9/72, p. 41

The secret of A. H. Robins's marketing success, 10/72, p. 32

The Vaseline Intensive Care line, 10/72, p. 72

Noxzema: the marketing magic of multiple uses, 11/72, p. 53

How Mitchum cracked the antiperspirant market, 12/72, p. 35

Can a new fragrance succeed in the off-season? 2/73, p. 20

Jean Naté: selling the bath as a pleasurable experience, 3/73, p. 35

Mennen E: creating a deodorant with a difference, 4/73, p. 39

Chanel No. 19, 5/73, p. 42

Love: how to launch a cosmetic line, 7/73, p. 26

Cover Girl, 7/73, p. 38

How Chap Stick came in from the cold, 8/73, p. 61

Dark Eyes: what attention-getting ads can do, 9/73, p. 84

How Estée Lauder planned for Christmas 1973, 10/73, p. 33

Lanvin's two new fragrances rely on fashion, glamour, 11/73, p. 38

Germaine Monteil: How to compete with the giants, 12/73, p. 28

MENLEY & JAMES LABORATORIES

The role of the proprietary product manager, 4/73, p. 34

Marketing case history: Love: how to launch a cosmetic line, 7/73, p. 26

MENNEN CO.

How the product manager system works at Mennen, 10/72, p. 84

Marketing case history: Mennen E: creating a deodorant with a difference, 4/73, p. 39

The short unhappy life of Mennen E, 8/73, p. 28

MILITARY MARKET
Tapping the military market, 10/73, p. 70

MILLER-MORTON CO.
How Chap Stick came in from the cold, 8/73, p. 61

MITCHUM-THAYER
Marketing case history: How Mitchum cracked the antiperspirant market, 12/72, p. 35

MONTEIL, GERMAINE
How to compete with the giants, 12/73, p. 28

NATIONAL ASSOCIATION OF RETAIL DRUGGISTS
The independent pharmacist: where is he heading?, 4/73, p. 43

NELSON, GAYLORD
Sen. Gaylord Nelson vs. the drug industry, 11/72, p. 91
Nelson introduces bill to curb 'pricing excesses' (Washington Brief), 11/72, p. 5
Nelson presses hearings; scientists attack ads, overprescribing (Washington Brief), 1/73, p. 5
Nelson's FD&C Act amendments due for replay this session (Washington Brief), 4/73, p. 12
Senator Nelson attacks industry's domestic price schedules (Washington Brief), 8/73, p. 10

NOXELL CORP.
Noxzema: the marketing magic of multiple uses, 11/72, p. 53
Marketing case history: Cover Girl, 7/73, p. 38

PACKAGING
New challenge for the package designer, 11/72, p. 77
12-tablet aspirin packs gain short reprieve (Washington Brief), 5/73, p. 12
Deadline is set for safety packaging of oral Rx drugs (Washington Brief), 6/73, p. 10
Prize-winning paperboard packages, 7/73, p. 59
Consumer safety panel eyes drug packaging, OTCs (Washington Brief), 10/73, p. 12

PAPERBOARD PACKAGING COUNCIL
Prize-winning paperboard packages, 7/73, p. 59

PATENTS
Carter-Wallace loses appeal on meprobamate patent (Washington Brief), 7/73, p. 8
Revolutionary patent-law proposals to be aired by Senate (Washington Brief), 9/73, p. 8
Government slates public inquiry on ampicillin patent charges (Washington Brief), 9/73, p. 24

PHARMACEUTICAL MANUFACTURERS ASSOCIATION
PMA attacks proposed environmental impact statements (Washington Brief), 11/72, p. 11
Court bars PMA intervention in complaint against FDA (Washington Brief), 11/72, p. 11
Price listing is outside FDA's sphere, PMA holds (Washington Brief), 12/72, p. 5
No legal curbs on human tests are needed, Stetler holds (Washington Brief), 4/73, p. 12
The 1962 drug amendments: time for an overhauling?, 5/73, p. 27
PMA protests abrupt action banning Violet No. 1 (Washington Brief), 6/73, p. 12
FDA cough/cold guides 'poorly conceived,' PMA asserts (Washington Brief), 7/73, p. 6
Drugstore inventory 'problem' doesn't exist, PMA study shows (Washington Brief), 8/73, p. 14
Kennedy drug-industry hearings could bring restrictive new laws (Washington Brief), 9/73, p. 8

PHARMACY
The independent pharmacist: where is he heading?, 4/73, p. 43
How voluntary drug chains affect the manufacturer, 5/73, p. 54
Drugstore inventory 'problem' doesn't exist, PMA study shows (Washington Brief), 8/73, p. 14

POPAI
Point-of-purchase advertising: it sells where people buy, 1/73, p. 27

POSITIONING
Trends from recent product introductions, 5/73, p. 38
Product positioning: the why and how, 6/73, p. 30
Dark Eyes: what attention-getting ads can do, 9/73, p. 84

PRODUCT INTRODUCTIONS
When should marketing take over from product development?, 3/73, p. 68
Trends from recent product introductions, 5/73, p. 38

PRODUCT MANAGEMENT SYSTEM
The role of the ethical product manager, 9/72, p. 21
How the product manager system works at Mennen, 10/72, p. 84
Product management at Coty: the total marketing concept, 11/72, p. 48
Why product managers change jobs so often, 1/73, p. 40
How to cope with the paper-work jungle, 3/73, p. 40
When should marketing take over from product development?, 3/73, p. 68
The role of the proprietary product manager, 4/73, p. 34
Marketing and R&D: natural enemies?, 5/73, p. 33
The marketing plan: just for show?, 7/73, p. 31

PRODUCT NAMES
The game of the name, 4/73, p. 29

PROMOTION
Top HBA promotions—summer, 1972, 11/72, p. 44
Top HBA promotions—fall, 1972, 2/73, p. 40
Top HBA promotions—winter, 1972-73, 5/73, p. 72
Medical promotion to the young MD, 6/73, p. 38
Top HBA promotions—spring, 1973, 8/73, p. 32
Top HBA promotions—summer, 1973, 11/73, p. 30
How to calculate the payout on a marketing program, 12/73, p. 23

PROPRIETARY ASSOCIATION
PA denies disclosure law applies to private sector data (Washington Brief), 9/72, p. 7
PA, broadcasters adopt guidelines for TV advertising (Washington Brief), 4/73, p. 9

PROPRIETARY PERFUMES LTD.
Proprietary Perfumes Ltd. enters the U. S. market, 6/73, p. 63

PUBLIC RELATIONS
How public relations can complement your marketing program, 2/73, p. 25

RESEARCH AND DEVELOPMENT
Marketing and R&D: natural enemies?, 5/73, p. 33

REVLON
Marketing case history: can a new fragrance succeed in the off-season?, 2/73, p. 20
John Revson's innovation approach to marketing, 3/73, p. 52

ROBINS, A. H.
The secret of A. H. Robins's marketing success, 10/72, p. 32

RUBINSTEIN, HELENA
How Rubinstein beats lack of assistance in self-service stores, 1/73, p. 47

SAMPLING
Consumer sampling: can it work for your product?, 1/73, p. 34
How to buy a sampling service, 10/73, p. 23

SURVEYS
What the public spent for drugs, cosmetics, toiletries in 1971, 9/72, p. 33
How drug and cosmetic firms fared financially, 10/72, p. 41
Top HBA promotions—summer, 1972, 11/72, p. 44
How the drug industry views its economic health, 2/73, p. 17
Top HBA promotions—fall, 1972, 2/73, p. 40
Top HBA promotions—winter, 1972-73, 5/73, p. 72
Top HBA promotions—spring, 1973, 8/73, p. 32
1972 ad expenditures for health and beauty aids, 8/73, p. 44
How drug and cosmetic firms fared financially, 9/73, p. 43
What the public spent for drugs, cosmetics, toiletries in 1972, 10/73, p. 43
Top HBA promotions—summer, 1973, 11/73, p. 30

SWEETENERS, NONNUTRITIVE
The search for a new artificial sweetener, 10/72, p. 27
Abbott to revive cyclamate food-additive petition (Washington Brief), 10/73, p. 9

THIRD-PARTY PAYMENT
Outpatient drug bill is revived by Senator Hartke (Washington Brief), 10/72, p. 7
Outpatient drugs could cut Medicare costs, proponents hold (Washington Brief), 3/73, p. 5
Confrontation with White House looms over Kennedy's HMO bill (Washington Brief), 7/73, p. 10
HEW proposes that Medicaid patients pay part of Rx cost (Washington Brief), 8/73, p. 8.
Third-party drug program called antitrust violation (Washington Brief), 8/73, p. 14

UNIT-DOSE SYSTEM
GAO approval of unit-dose system could influence Congress (Washington Brief), 1/73, p. 5 ■